The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
Cipla and Ethris partner for the development of mRNA-based therapies
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
The advanced laboratory spread over 2,200 Square feet has multiple laboratory divisions including Hematology, Biochemistry, Clinical pathology, Serology and Microbiology
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
Her previous role at Novartis, where she was general manager, data & digital, in global drug development, also included accountability for driving the DCT strategy, programs and platforms
To focus on providing safer burn treatments for women and armed forces
Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks
Subscribe To Our Newsletter & Stay Updated
